menu search

Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...

October 25, 2023, 9:26 pm

Opko health to present new clinical data on rayaldee (er calcifediol) at kidney week 2023

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical<...

October 25, 2023, 8:25 pm

Opko health to present new clinical data on rayaldee (er calcifediol) at kidney week 2023

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical...

October 25, 2023, 4:25 pm

New data from biogen’s investigational antisense oligonucleotide (aso) targeting tau shows promise for potential new generation of treatments in early alzheimer’s disease

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau ta...

October 25, 2023, 2:51 pm

Biovie says blinded data points to hopeful alzheimer's treatment potential

BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th clinical Trials on Alzheimer's Di...

October 25, 2023, 2:19 pm

Why alkermes stock is sinking today

Alkermes' third-quarter results beat Wall Street's expectations. However, investors appeared to still be disappointed with a ...

October 25, 2023, 12:38 pm

Acceptance of polyamine inhibitor car-t combination abstract for online publication

MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...

October 25, 2023, 12:15 pm

Reneo pharmaceuticals announces poster presentation at upcoming scientific meetings

IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical...

October 25, 2023, 11:50 am

Why is bioxcel therapeutics (btai) stock up 42% today?

BioXcel Therapeutics (NASDAQ: BTAI ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its...

October 25, 2023, 9:18 am

Carisma to present first results from in vivo car-m collaboration with moderna at sitc 2023

-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data ...

October 25, 2023, 9:11 am

Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage...

October 25, 2023, 9:05 am

Fate therapeutics to webcast conference call reporting third quarter 2023 financial results

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a ...

October 25, 2023, 8:00 am

Altimmune to present new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in a late-breaking presentation at the liver meeting® 2023

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage bi...

October 25, 2023, 7:30 am

Bioxytran gets broad patent coverage on 60+ viruses

Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTR...

October 24, 2023, 12:45 pm

Aclarion announces nociscan® cost-effectiveness poster presented at 45th annual smdm meeting

Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SM...

October 24, 2023, 12:45 pm

Panbela to host third quarter 2023 earnings conference call on november 9, 2023

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...

October 24, 2023, 12:15 pm

Lisata therapeutics announces first patient treated in the cholangiocarcinoma cohort of the bolster trial of lsta1, a novel tumor-targeting and penetrating peptide

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-car...

October 24, 2023, 12:00 pm

Moderna and caris life sciences partner to develop mrna oncology therapeutics

Moderna Therapeutics Inc (NASDAQ:MRNA) has teamed up with Texas-headquartered private precision medicine and molecular science firm Caris Life Science...

October 24, 2023, 10:21 am

Oxford cannabinoid technologies delighted with phase 1 outcome for pain drug

Clarissa Sowemimo-Coker, CEO of Oxford Cannabinoid Technologies Holdings, discusses with Proactive's Thomas Warner the successful completion of a phas...

October 24, 2023, 9:46 am

Spectral ai taps paul chadwick to lead deepview global expansion

Spectral AI Inc (NASDAQ:MDAI) is beefing up its executive team in the UK with the addition of Prof Paul Chadwick. Chadwick, a distinguished ...

October 24, 2023, 8:43 am


Search within

Pages Search Results: